Introduction
============

Papillomaviruses (PVs) are DNA tumor viruses and infect squamous or mucosal epithelia ([@b38]). To date, there are over 100 different human PV (HPV) genotypes that have been fully sequenced and can be divided into low-risk, non-oncogenic, or high-risk oncogenic types ([@b8]; [@b1]) by their viral ability to cause malignant disease ([@b29]) ([Table 1](#tbl1){ref-type="table"}). The predominant low-risk types are HPV 6 and 11 and cause 90% of genital warts (condyloma acuminata) while HPV 16 and 18 are the most prevalent high-risk types, causing 70% of cervical cancer and cervical intra-epithelial neoplasia (CIN) ([@b8]) and are considered to be the most destructive oncogenic viruses worldwide. Globally, the incidence and mortality rates of new cases, caused by HPV-related cervical cancer were estimated to be approximately 500,000 in 2002 ([@b12]). In addition, it is estimated that sexually active men and women have a 50% lifetime risk of HPV infection ([@b42]).

###### 

The major high- and low-risk HPV types

  Classification          HPV types
  ----------------------- ------------------------------------------------------------
  High-risk types         16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, 82
  Low-risk types          6, 11, 40, 42, 43, 44, 54, 61, 70, 72, 81, CP6108
  Potentially high-risk   26, 53, 66

Interestingly, although the prevalence of HPV DNA among most sexually active women in the general population is high, these infections are generally transient and infected individuals are able to eliminate the virus without intervention and do not develop cancer ([@b24]). Thus an effective host immune response and the genetic make-up of the individual may be an important determinant for the persistence and progression of HPV induced cervical cancer ([@b27]). Consequently, several studies have investigated genetic host factors and immune responses, to describe the association between genital HPV infection and cervical cancer ([@b37]; [@b11]; [@b18]). Although these investigations have not elucidated the role of a few genetic host factors for the development of cervical cancer these studies emphasize the possible variability of genetic host factors and ethnic disparity in diverse population groups and should thus, not be viewed in isolation as other confounding factors may contribute to the progression of disease ([@b16]).

Current therapies for HPV-related disease
=========================================

Up until now the current approaches for the treatment and control of HPV-related infections have been variable. Although condoms may afford some protection, infection by HPV types may still occur via the unprotected areas of the genital skin ([@b4]). In addition, despite the widely adopted and effective cervical cytology screening test, Papanicolaou (Pap) smear, the incidence of new HPV-induced infections remains a global public health problem, particularly in developing countries where cervical cancer is the most common cancer among women ([@b42]). The main contributing factors that are responsible for this health problem in several countries is due to the lack of established and stringent routine screening programs and even in developed nations the disadvantaged minorities may not have access to cervical cancer screening ([@b33]). Furthermore, the accepted treatments for HPV-related disease are limited, uncomfortable, invasive, costly and ineffi cient with a high relapse rate ([@b31]). Therefore, a preventative treatment approach such as the development of a prophylactic vaccine would be the most cost effective means to reduce the incidence of HPV-related infections.

Biology of PV
=============

When selecting vaccine targets an understanding of the molecular pathogenesis of PV-associated infections is central, as PVs are able to evade the host immune system in the early stages of carcinogenesis. The lifecycles of PVs are linked to the differentiation stages of the host epithelial cells, and replication is restricted exclusively to the stratifi ed squamous epithelium ([@b13]). PVs are small, non-enveloped viruses containing a 8kb double-stranded closed circular DNA genome, encoding six early proteins (E1, E2, E4, E5, E6 and E7), two late proteins (L1 and L2) and a non-coding regulatory region, the long-control region (LCR) ([@b43]). The general organization of the HPV genome is shown in [Figure 1](#fig1){ref-type="fig"}. The early genes contribute to transformation and viral replication, the late genes provide capsid proteins and the LCR contains the origin of replication ([@b43]).

![A linearized general organization of the HPV 16 genome (7.905 base pairs) showing the long control region (LCR), the early (E), and late (L) genes.](tcrm0401-65-01){#fig1}

Rationale for a preventative vaccine
====================================

As PVs are host and tissue specific, several animal PV models have been developed and have provided significant information for vaccine development. In particular, preclinical studies using the cottontail rabbit papillomavirus (CRPV) in rabbits, bovine papillomavirus (BPV) in cattle and canine oral papillomavirus (COPV) in dogs have successfully provided a better understanding of the molecular mechanism that regulate normal cell growth, steps involved in cancerous cell changes ([@b13]) and have tested the potential of different delivery systems ([@b3]; [@b23]; [@b2]; [@b17]).

It has been shown that the expression of PV L1 genes in vitro results in the assembly of virus-like particles (VLPs) and induces high titers of virus-neutralizing serum antibodies when administered as an immunogen ([@b22]; [@b6]). Although VLPs are morphologically and antigenically almost indistinguishable from the native HPV virion, they are non-infectious, lack viral DNA, and most importantly they are highly immunogenic and afford protection from papillomavirus challenge. Due to the encouraging animal studies, efforts to produce a vaccine against HPV-induced infections were centered on the major capsid protein, L1 VLPs and were translated into human phase I clinical trials.

Efficacy trials
===============

In a placebo-controlled human clinical trial, women who were HPV 16 negative, at the time of vaccination, were protected 17.4 months post HPV 16 L1 VLP vaccination from the development of CIN ([@b25]). This yeast produced HPV 16 VLP vaccine was 100% efficacious in the prevention of HPV16-induced infection. Consequently, following on the successful human clinical trials, two pharmaceuticals companies, GlaxoSmithKline (GSK) and Merck & Co developed bivalent and quadrivalent HPV-VLP L1 vaccines respectively. GSK assessed the efficacy of a bivalent HPV16/18 VLP vaccine. The L1 protein of each type was expressed via a recombinant baculovirus vector where the resulting VLPs were combined to produce the vaccine, Cervarix™. Cervarix has been shown to be efficacious through 4.5 years, highly immnuonogenic and safe, and there is evidence of cross-protection against incident infection with HPV types 31 and 45 ([@b20]). The quadrivalent vaccine by Merck and Co was prepared in a yeast system and the expressed L1 protein of each type was combined to generate Gardasil^®^. To date, Gardasil has been shown to be highly effective trough 5 years in the prevention of HPV induced disease ([@b41]). The description and composition of Cervarix and Gardasil are tabulated in [Table 2](#tbl2){ref-type="table"}. This review will focus only on the results generated from the clinical trials of Gardasil (manufactured by Merck and Co, Inc, Whitehouse Station, New Jersey). The efficacy data of the randomized, placebo-controlled efficacy trials of the HPV L1 VLP vaccines are summarized in [Table 3](#tbl3){ref-type="table"} and the important recommendations stated by the Advisory Committee on Immunization Practices (ACIP) are tabulated in [Table 4](#tbl4){ref-type="table"}.

###### 

Description and composition of the bivalent and quadrivalent HPV-L1 vaccines in human clinical trials

                                    Gardasil^®^                                                                   Cervarix™
  --------------------------------- ----------------------------------------------------------------------------- -----------------------------------------------------------
  1\. Company                       Merck & Co                                                                    GlaxoSmithKline
  2\. Vaccine formulation           VLP derived from HPV 6, 11, 16 and 18                                         VLPs derived from HPV 16 and 18
  3\. Composition                   Produced in a yeast system                                                    Produced in an insect-cell system
  4\. Route of administration       Intramuscular                                                                 Intramuscular
  5\. Dose schedule                 three-dose regime 0, 2, and 6 months                                          three-dose regime 0, 1, and 6 months
  6\. Dosages                       0.5 mL (containing 20 μg HPV6, 40 μg HPV11, 40 μg HPV16 and 20 μg HPV18 VLP   0.5 mL (containing 20 μg HPV16 and 20 μg HPV18
  7\. Adjuvant                      225 μg of aluminium hydroxyphosphate sulphate (alum)                          50 μg of aluminium hydroxide with 50 μg of AS04
  8\. Current analysis of vaccine   Safe, well tolerated and 100% efficacious                                     Safe, well tolerated and 100% efficacious
  9\. Sustained efficacy            Effective through 5 yrs[a](#tf2-1){ref-type="table-fn"}                       Effective through 4.5 yrs[b](#tf2-2){ref-type="table-fn"}
  10\. Licensed for public use      \>60 countries                                                                Australia (women ≤45 yrs)

[@b41].

[@b20].

###### 

Summary of the randomized, human placebo-controlled efficacy trials of Gardasil^®^

  VLP vaccine                                      Vaccine/placebo group   Vaccine schedule   Duration of trial (months)   Vaccine efficacy (HPV vaccine type) % (95% CI)
  ------------------------------------------------ ----------------------- ------------------ ---------------------------- ------------------------------------------------
  HPV 16[a](#tf3-1){ref-type="table-fn"}           765/768                 0, 2, 6            17                           100 (90--100)
  HPV 6/11/16/18[b](#tf3-2){ref-type="table-fn"}   277/275                 0, 2, 6            35                           89 (70--97)
  HPV 6/11/16/18[c](#tf3-3){ref-type="table-fn"}   104/120                 0, 2, 6            60                           95 (69--100)

[@b25].

[@b40].

[@b41].

###### 

Selected recommendations by ACIP[a](#tf4-1){ref-type="table-fn"} for the use of Gardasil^®^ following on from its licensure

  Vaccination program                  Recommendations
  ------------------------------------ -----------------------------------------------------------
  1\. Route of administration          Intramuscular
  2\. Dose schedule                    Three-dose regime (0, 2, and 6 months)
  3.Age of females at vaccination      [b](#tf4-2){ref-type="table-fn"}9, 11--12 yrs
  4\. Catch-up age at vaccination      [c](#tf4-3){ref-type="table-fn"}13--26 yrs
  5\. Post-vaccination                 Routine cervical cancer screening is compulsory
  6\. Vaccination of males             Not recommended (the efficacy data are not yet available)
  7\. Groups not included in program   Females \>26 yrs (data not yet available)
                                       Females \<9 yrs

ACIP -- Advisory Committee on Immunization Practices ([@b28]).

It is recommended that females as young as 9 years can be vaccinated.

These are females that have not been previously vaccinated.

Drawbacks of the quadrivalent vaccine
=====================================

Type specificity
----------------

It has been shown in pre-clinical animal challenge models ([@b3]) and clinical human trials ([@b25]) that immunization with a type-specific PV L1 VLP will elicit protection only to the same homologous PV type. In addition, it was reported that in a clinical human trial, women who were vaccinated against HPV 16 L1 VLP, a number of women developed CIN lesions that were induced by other HPV types other than HPV 16 ([@b25]). However, it should be noted that evidence of cross-protection has been shown in Cervarix against infection with HPV 31 and HPV 45. Nevertheless, it is estimated that the preventative quadrivalent vaccine will not provide protection against the almost 30 % of cervical cancers that are from types other than HPV-16 /18 ([@b35]). In addition, this prophylactic vaccine will only be effective for those individuals that have not been exposed to the high-risk HPV types ([@b21]) as the therapeutic potential of the low-risk types vaccine have not been established.

One of the current thoughts that may circumvent the lack of broad cross-protection is the use of the minor capsid protein, L2. Recently several studies have demonstrated that L2-based vaccines have broad cross-neutralizing epitopes and would thus induce cross-protective immunity to different HPV types ([@b32]; [@b7]; [@b30]). While L2-based vaccines have broad cross-protection, the neutralizing antibody titres generated are much lower than the current candidate VLP L1-based vaccines. The prophylactic potential of L2 based vaccines can possibly be increased by L2 codon optimization or generating a L2 peptide-based vaccine. Nevertheless, it is suggested that extensive pre-clinical studies should be conducted to elucidate ways of increasing the immunogenicity of L2-based vaccines.

Availability of the quadrivalent vaccine in developing countries
----------------------------------------------------------------

The cost effectiveness of the current quadrivalent vaccine has been examined using the Markov mathematical model ([@b34]; [@b15]; [@b39]). This model was used to estimate the cost per quality-adjusted life year (QALY) and deliberate on the impact and cost of HPV vaccination for a given group, without considering the effect of vaccination on HPV transmission in the population ([@b15]; [@b28]). One model estimated that the lifetime risk for cervical cancer in the vaccinated group would be reduced by 58% and the incidence of cervical cancer would be reduced by 20% compared with no vaccination ([@b15]). However, as these models have been estimated for developed countries where vaccination coverage would probably be 70%--100%, widespread distribution of the vaccine will not be achieved in developing countries where the vaccines are needed most. Given that the burden of cervical cancer in most developing countries is attributed to poverty, lack of education, lack of effective screening programs, lack of resources (human and financial) and infrastructure ([@b9]), widespread distribution of the vaccine will not be successful. In addition, the vaccines would need proper cold chain for storage as the route of administration is intramuscular making it too expensive to distribute in low-resource settings. It is suggested that funding sources and commercial companies should provide or assist the low-resource communities with financial and perhaps human resources for the distribution of the prophylactic vaccine in conjunction with a routine screening program for cervical disease.

Public health burden in developing countries
--------------------------------------------

A further significant health problem in developing countries is infection with the human immunodeficiency virus (HIV). In sub-saharan Africa the epidemic has grown exponentially over the past 15 years making it the worst HIV epidemic in the world ([@b10]) and the availability of antiretroviral therapies are limited. In addition, it has been reported that HIV positive women are at an increased risk of developing cervical squamous intra-epithelial lesions (SIL) and cervical cancer ([@b26]; [@b36]). Moreover, cervical cancer is included as one of the defining conditions of the acquired immune deficiency syndrome (AIDS) ([@b5]). Thus, this health problem would render a significant portion of the sexual active population immunocompromised and will probably render the quadrivalent vaccine ineffective.

Therapeutic potential of Gardasil
=================================

Recently, in a Phase III community based randomized trial, it has been demonstrated that vaccination with a bivalent HPV-16/18 L1 VLP vaccine did not induce viral clearance in women with existing HPV induced infection ([@b21]). However, there are no placebo-controlled human trials that show the therapeutic benefit of the low-risk HPV types vaccines that have been included in Gardasil. For this HPV VLP L1 vaccine to afford a positive therapeutic effect, a strong cytotoxic T-cell (CTL) response should be elicited. However, given that the important stages in the development of cervical cancer are, integration of the viral genome into the host cell chromosomes and the consistent expression of HPV E6 and E7 proteins in cervical cancer cells, the L1 gene may be disrupted ([@b33]). Therefore, the low levels of L1 will not induce a L1-specific CTL response and the elimination of established HPV-induced lesions will be not be achieved by the VLP L1 quadrivalent vaccine.

However, as discussed above, L2 based vaccines show promise as a potential candidate for the next generation of prophylactic vaccines. L2 based vaccines have also been tested in a therapeutic setting and have provided encouraging results in the CRPV rabbit challenge model ([@b19]). It was demonstrated that the regression of CRPV-induced papillomas was achieved following immunization of rabbits with recombinant Bacille Calmette-Guerin rBCG expressing CRPVL2 or CRPVL2E7E2 proteins ([@b19]). This L2-based vaccine approach is promising and warrants further preclinical investigations to increase the efficacy of a possible combined prophylactic and therapeutic candidate vaccine.

Conclusion
==========

The development of the current effective quadrivalent vaccine is a major breakthrough in HPV research. Indeed, the vaccine will serve to significantly reduce the burden of HPV related anogenital infections in young women worldwide. However, it should be clear from this review that this quadrivalent vaccine is not the ideal vaccine for developing countries and fervent basic scientific research need to continue and build on what we already know. For instance, work on L2 needs to continue to potentially provide a broad cross-protection and second generation HPV vaccine. Issues of vaccine availability and cost in the developing countries also need to be addressed with the aim being to reduce the global burden of HPV disease rather than only in countries that can afford vaccines.
